Novo Nordisk Halts Two Late-Stage Ziltivekimab Studies After Futility Review
Novo Nordisk has discontinued two additional late-stage clinical trials of its IL-6 inhibitor ziltivekimab. The decision came after the studies' independent data monitoring committee concluded that the drug was unlikely to demonstrate a meaningful benefit. The company did not provide further details on the remaining development program for the candidate.
Expanded Detail
EXPANDED:
The
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Spyre halts RA program for anti-TL1A candidate after Phase 2 disappointment · Drug development
Capricor's Duchenne therapy faces delayed FDA decision due to additional data review · Drug development
Regenxbio's Hunter syndrome gene therapy hits second regulatory snag · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Novo Nordisk cans two more trials of IL-6 heart drug for futility.” Browse more stories.